PreveCeutical Converts Acidic Phytocannabinoids to Neutral Form and Doubles Contents of Fingerprinted Cannabis Extract Library
Vancouver, British Columbia–(Newsfile Corp. – November 20, 2018) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the « Company » or « PreveCeutical »), announces that it has developed an optimized protocol to convert phytocannabinoids extracted from the Company’s five cannabis strains from their acid forms to their neutral forms (the « Neutralization Protocol »).
Specifically, the Company’s Neutralization Protocol has confirmed the comprehensive conversion of cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) to their neutral forms, canabidiol (CBD) and tetrahydrocannabinol (THC), respectively, without generating any detectable degradative products in the process. Further, the Neutralization Protocol has been verified via High-Performance Liquid Chromatography (HPLC) analysis using commercial cannabinoid standards.
The successful conversion of phytocannabinoids from their acid to neutral forms is an important development from a clinical perspective, as reports continue to emerge highlighting the benefits of using both acid and neutral forms of cannabinoids in treating a range of diseases and ailments.
As a result of the Neutralization Protocol, PreveCeutical has now doubled the number of extracts in its fingerprinted cannabis extract library by adding the five neutral form cannabinoid extracts to the five acid form cannabinoid extracts which were entered into the library earlier in 2018. For further information on the fingerprinted cannabis extract library (see news releases dated September 4, 2018, and November 5, 2018).
Next, the Company intends to pursue independent incorporation of both the acid and neutral form extracts into its soluble gel drug delivery program (the « Sol-gel Program ») to generate a range of cannabinoid-based soluble gel formulations (each, a « CBD Sol-gel Formulation »), complemented by the Company’s custom soluble gel applicator device (the « Sol-gel Applicator ») for nose-to-brain drug delivery.
The Company’s Chief Research Officer, Dr. Harendra Parekh stated, « Having optimized the conditions for comprehensive conversion of phytocannabinoids from acid to neutral forms opens the door to a wider product range for PreveCeutical, which is aimed at meeting the ever-increasing demands by physicians and patients alike, for chemically-validated, dose-standardized products. »
The CBD Sol-gel Formulations, when used with the Company’s Sol-gel Applicator, will facilitate prolonged delivery of cannabinoids to patients’ central nervous systems. The Company’s medicinal cannabis division expects to be able to offer a broad product range that can be tailored to specific medical conditions. For example, the Company is currently developing a CBD Sol-gel Formulation with a cannabinoid composition designed to treat patient anxiety (see news release dated August 8, 2018).
PreveCeutical’s Sol-gel Applicator is currently in development. The Company’s research partner, the University of Queensland, has received several prototypes for the Sol-gel Applicator from the Company’s manufacturer, and has been assessing their performance in the Sol-gel Program.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
« Stephen Van Deventer »
Chairman, CEO and President
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, « forward-looking statements ») within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of the Sol-gel Program, the utilisation of the Neutralization Protocol, the development of the Sol-gel Formulations and the Sol-gel Applicator, the efficacy of the Company’s products, matters related to the Company’s current and planned research and development programs, including the Sol-gel Program, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as « plans », « expects », « may », « intends », « anticipates », « believes », « proposes » or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research programs as planned and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.